Infinity Pharmaceuticals has partnered with AbbVie to develop and commercialise its duvelisib (IPI-145), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K gamma, to treat patients with cancer.

Duvelisib has shown clinical activity against different blood cancers, such as indolent non-Hodgkin’s lymphoma (iNHL) and chronic lymphocytic leukemia (CLL).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

AbbVie executive vice-president and chief scientific officer Michael Severino said: "We believe that duvelisib is a very promising investigational treatment based on clinical data showing activity in a broad range of blood cancers."

"We believe that duvelisib is a very promising investigational treatment based on clinical data showing activity in a broad range of blood cancers."

As part of the deal, Infinity will receive an upfront payment of $275m and is eligible to secure around $530m in additional payments upon the achievement of development, regulatory and commercial milestones, including $405m for the achievement of milestones through the first commercial sale of duvelisib.

Both companies will jointly commercialise duvelisib in the US, while AbbVie will take the responsibility of commercialisation outside the US.

Infinity has initiated registration-focused trials to evaluate the safety and efficacy of duvelisib, including Dynamo, a Phase II study in patients with iNHL, and Duo, a Phase III study in patients with CLL.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Infinity chair, president and chief executive officer Adelene Perkins said: "This collaboration is an important step toward fulfilling Infinity’s objective of bringing better treatments to patients and further advances our goal of building a sustainable, fully integrated biotechnology company.

"AbbVie will be a wonderful partner for Infinity, bringing all of the expertise and scale of a successful, well-established company, together with the energy, drive, innovation, and nimbleness of a young organisation."